4.6 Article

Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples

期刊

NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 27, 期 7, 页码 2839-2847

出版社

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfr795

关键词

apolipoprotein; ARIC; chronic kidney disease; epidemiology; NHANES

资金

  1. National Heart, Lung and Blood Institute [HHSN268201100005C, HHSN268201100006C, HHSN2682011000 07C, HHSN268201100008C, HHSN268201100009C, HHSN2682 01100010C, HHSN268201100011C, HHSN268201100012C]
  2. Emmy Noether Program of German Research Foundation [KO 3598/2-1]
  3. [U01HL075572-01]

向作者/读者索取更多资源

lipoprotein risk factors for atherosclerosis, i.e., increased LDL cholesterol, increased triglycerides and decreased HDL cholesterol, also are associated with progression of loss of kidney function...Goek and coworkers describe the association of the apoliproteins A1 and B and eGFR in two large cohorts derived from the general polulation [the NHANES III (N=7,023) and the ARIC study (n=10,292)]. The results were similar in both cohorts...Circulating lipoproteins and their protein constituents, apolipoproteins, are risk factors for chronic kidney disease (CKD). The associations between apolipoprotein A1, apolipoprotein B and their ratio with glomerular filtration rate estimated from the new CKD Epidemiology Collaboration (CKD-EPI) equation (eGFR) are not well studied in the general population. Associations between apolipoprotein A1, B and their ratio with the outcomes of eGFR, CKD (eGFR 60 mL/min/1.73m(2)) and albuminuria were examined in the Atherosclerosis Risk in Communities study (ARIC, n 10 292, 199698) and the Third National Health and Nutrition Examination Survey (NHANES III, n 7023, 198891). Cross-sectional multivariable-adjusted analyses were performed using linear and logistic regression. Prospective analyses related baseline apolipoprotein levels to subsequent CKD incidence over 10 years using the ARIC Carotid MRI follow-up cohort (n 1659). Higher apolipoprotein A1 quartiles were associated with a lower prevalence of CKD [Q4 versus Q1: odds ratio (OR) 0.73, P-trend 0.02 in ARIC; Q4 versus Q1: OR 0.53, P-trend 0.01 in NHANES III] as well as with higher eGFR (P-trend 0.01 in ARIC and NHANES III). No consistent significant associations were found for apolipoprotein B in either study. The apolipoprotein B/A1 ratio was significantly associated with eGFR across quartiles in both studies (P-trend 0.01) and with CKD in ARIC (Q4 versus Q1: OR 1.23, P-trend 0.01). Prospectively, there were trends for the association of apolipoproteins with incident CKD [Q4 versus Q1: incidence rate ratio (IRR) 0.68 for apolipoprotein A1, P-trend 0.1; Q4 versus Q1: IRR 1.35 for apolipoprotein B, P-trend 0.2]. Associations were not systematically stronger when comparing traditional lipids (total cholesterol, low-density lipoprotein or high-density lipoprotein) to apolipoproteins. Higher serum apolipoprotein A1 was associated with lower prevalence of CKD and higher eGFR estimated by the CKD-EPI equation in two large multiethnic population-based samples. While apolipoprotein B showed no consistent associations, a higher apolipoprotein B/A1 ratio was significantly associated with lower eGFR in both studies. The direction and magnitude of the longitudinal associations between apolipoproteins and CKD incidence were overall similar to those observed cross-sectionally. No consistent differences became apparent between traditional lipids and apolipoproteins.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据